Abstract
New reports offer evidence that under different circumstances, intrauterine mother-infant transmission of SARS-CoV-2 occurs. In contrast, early observations in the COVID-19 pandemic recommended that vertical transmission from women infected with SARS-CoV-2 can be challenging and no virus is detected in human amniotic fluid (HAF). The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis. Considering that COVID-19 can cause a severe pulmonary fibrotic response in some patients, HAF by decreasing fibrosis may be considered as an alternative and novel therapy against COVID-19. Lastly, given the inexpensive, easy to access, and safe nature of HAF, integrating this therapy may decrease the COVID-19 attributed death and burden to the health system, especially in countries with limited access to vaccines where HAF is widely available.
Highlights
SARS-CoV-2, the virus that causes COVID-19, has emerged recently and spread rapidly to 219 countries and territories, causing over 103,985,844 infections with 2,249,445 deaths so far [1]
Early observations in the COVID-19 pandemic recommended that vertical transmission from women infected with SARS-CoV-2 can be challenging and no virus is detected in human amniotic fluid (HAF) [8, 9]
The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis
Summary
SARS-CoV-2, the virus that causes COVID-19, has emerged recently and spread rapidly to 219 countries and territories, causing over 103,985,844 infections with 2,249,445 deaths so far [1]. The fatality rate of COVID-19 disease was initially reported to be 15%, but this estimate was calculated from a small group of hospitalized patients. A distinctive feature of the SARS-CoV-2 is its high contagiousness and rapid spread between people, which has led to a severe outbreak of the COVID-19 disease [3]. The Open Biology Journal, 2021, Volume 9 37 measures for completely different clinical situations. This may shed light on the need for novel and effective treatment apart from the availability of vaccines against COVID-19 disease. The present study aimed to propose the idea that HAF can be used as a potential therapy for hospitalized, symptomatic, and laboratory-verified SARS-CoV-2 patients by mitigating COVID-19 related inflammation and decreasing its fibrosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
